FindTrial
Sign In

Standard Adjuvant Endocrine Therapy

DRUG2 trials

Sponsors

Alliance Foundation Trials, LLC., Eli Lilly and Company

Conditions

Breast Cancer

Phase 3

PALbociclib CoLlaborative Adjuvant Study
Active, not recruitingNCT02513394
Alliance Foundation Trials, LLC.Breast Cancer
Start: 2015-08-01End: 2028-12-01Updated: 2026-06-15
Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast Cancer
Active, not recruitingNCT03155997
Eli Lilly and CompanyBreast Cancer
Start: 2017-07-12End: 2029-05-01Updated: 2026-04-24

Related Papers

Risk stratification and age-related disparities with abemaciclib responses in early ER-positive/HER2-negative breast cancer.
Journal of Clinical Oncology2026-05-28
Abstract RF3-04: Tumor-informed circulating tumor DNA analysis to assess molecular residual disease for prognosis and prediction of benefit from palbociclib in the PALLAS trial
Clinical Cancer Research2026-02-17
Overall survival with abemaciclib in early breast cancer.
2025-10-171 citations
Abstract P4-11-14: Prescribing patterns and real-world clinical usage of adjuvant abemaciclib for early-stage, high-risk, hormone receptor positive breast cancer
Clinical Cancer Research2025-06-13
Abstract P1-08-15: Real-world analysis of breast cancer patients qualifying for adjuvant CDK4/6 inhibitors
Clinical Cancer Research2025-06-13
Treatment-related neutropenia as a predictor of response to adjuvant palbociclib in the PALLAS trial (ABCSG-42/AFT-05/BIG-14-13/PrE0109).
Journal of Clinical Oncology2025-05-28
Impact of body mass index (BMI) on efficacy and safety of abemaciclib in breast cancer patients (pts) treated in the monarchE trial.
Journal of Clinical Oncology2025-05-28
Impact of adding palbociclib on treatment adherence to ongoing adjuvant endocrine treatment in the global randomized PALLAS randomized trial in patients with early breast cancer.
2025-03-271 citations
Outcomes in stage IIA versus stage IIB/III in the PALLAS trial [ABCSG-42/AFT-05/PrE0109/BIG-14-13])
Breast Cancer Research2025-01-231 citations
Abemaciclib combined with endocrine therapy as adjuvant treatment for hormone-receptor-positive, HER2-, high-risk early breast cancer: 5-year Chinese population analysis of the phase III randomized monarchE study.
2024-10-234 citations
Real-World Analysis of Breast Cancer Patients Qualifying for Adjuvant CDK4/6 Inhibitors.
2024-08-2910 citations
Abemaciclib plus endocrine therapy for HR+, HER2-, node-positive, high-risk early breast cancer: a plain language summary of the monarchE study
Future Oncology2024-07-18
Prognostic utility of ctDNA detection in the monarchE trial of adjuvant abemaciclib plus endocrine therapy (ET) in HR+, HER2-, node-positive, high-risk early breast cancer (EBC).
Journal of Clinical Oncology2024-06-0530 citations
Analysis of the sensitivity to endocrine therapy (SET) assay in the PALLAS adjuvant trial of palbociclib in HR+/HER2- breast cancer (ABCSG-42/AFT-05/BIG-14-13).
Journal of Clinical Oncology2024-05-29
Abstract GS03-06: Genomic and transcriptomic profiling of primary tumors from patients with HR+, HER2-, node-positive, high-risk early breast cancer in the monarchE trial
Cancer Research2024-05-0211 citations
Abstract GS03-07: Protocol-defined biomarker analysis in the PALLAS (AFT-05) adjuvant trial: Genomic subtype derived from RNA sequencing of HR+/HER2- early breast cancer
Cancer Research2024-05-023 citations
Abstract PS06-01: Results from a pilot study exploring ctDNA detection using a tumor-informed assay in the monarchE trial of adjuvant abemaciclib with endocrine therapy in HR+, HER2-, node-positive, high-risk early breast cancer
Cancer Research2024-05-022 citations
Abstract PO1-01-08: The impact of drug-drug interactions between palbociclib and proton pump inhibitors on clinical outcomes of patients with hormone receptor positive, HER2-negative, early breast cancer: an exploratory analysis of the PALLAS study
Cancer Research2024-05-02
Abstract PO1-01-13: Clinical characterization, prognostic and predictive values of HER2-low in early breast cancer in the PALLAS trial
Cancer Research2024-05-02
Abstract PO1-13-01: Safety profiles of Chinese breast cancer patients who received abemaciclib in MONARCH plus and monarchE study
Cancer Research2024-05-02

27 more papers not shown